Switch theme
Sign up to access all valuation multiples
Founded in 2011, Samsung Biologics is a South Korean contract development and manufacturing organization with a global client base. Europe and the US contribute 90% of its total revenue. It provides end-to-end development and manufacturing services from cell line developments to final commercial manufacturing. As of 2023, Samsung Biologics had a total production capacity of 604,000 liters, one of the largest in the world. Its CDMO services account for 72.4% of its total revenue. The balance comes from subsidiary Samsung Bioepis, acquired in 2022. Samsung Bioepis is involved in developing and manufacturing biosimilars.
2011
n/a
LTM Revenue $3.6B
LTM EBITDA $1.5B
$53.5B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Samsung BioLogics has a last 12-month revenue (LTM) of $3.6B and a last 12-month EBITDA of $1.5B.
In the most recent fiscal year, Samsung BioLogics achieved revenue of $3.3B and an EBITDA of $1.5B.
Samsung BioLogics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Samsung BioLogics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $3.6B | XXX | $3.3B | XXX | XXX | XXX |
| Gross Profit | $1.9B | XXX | $1.7B | XXX | XXX | XXX |
| Gross Margin | 51% | XXX | 50% | XXX | XXX | XXX |
| EBITDA | $1.5B | XXX | $1.5B | XXX | XXX | XXX |
| EBITDA Margin | 41% | XXX | 44% | XXX | XXX | XXX |
| EBIT | $1.1B | XXX | $960M | XXX | XXX | XXX |
| EBIT Margin | 30% | XXX | 29% | XXX | XXX | XXX |
| Net Profit | $878M | XXX | $788M | XXX | XXX | XXX |
| Net Margin | 24% | XXX | 24% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $690M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Samsung BioLogics's stock price is KRW 1032000 (or $750).
Samsung BioLogics has current market cap of KRW 73.45T (or $53.4B), and EV of KRW 73.59T (or $53.5B).
See Samsung BioLogics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $53.5B | $53.4B | XXX | XXX | XXX | XXX | $12.34 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Samsung BioLogics has market cap of $53.4B and EV of $53.5B.
Samsung BioLogics's trades at 16.2x EV/Revenue multiple, and 36.4x EV/EBITDA.
Equity research analysts estimate Samsung BioLogics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Samsung BioLogics has a P/E ratio of 60.8x.
See valuation multiples for Samsung BioLogics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $53.4B | XXX | $53.4B | XXX | XXX | XXX |
| EV (current) | $53.5B | XXX | $53.5B | XXX | XXX | XXX |
| EV/Revenue | 14.7x | XXX | 16.2x | XXX | XXX | XXX |
| EV/EBITDA | 35.8x | XXX | 36.4x | XXX | XXX | XXX |
| EV/EBIT | 49.0x | XXX | 55.7x | XXX | XXX | XXX |
| EV/Gross Profit | 28.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | 60.8x | XXX | 67.8x | XXX | XXX | XXX |
| EV/FCF | 99.1x | XXX | 261.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSamsung BioLogics's last 12 month revenue growth is 20%
Samsung BioLogics's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Samsung BioLogics's rule of 40 is 66% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Samsung BioLogics's rule of X is 91% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Samsung BioLogics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 20% | XXX | 19% | XXX | XXX | XXX |
| EBITDA Margin | 41% | XXX | 44% | XXX | XXX | XXX |
| EBITDA Growth | 20% | XXX | 17% | XXX | XXX | XXX |
| Rule of 40 | 66% | XXX | 64% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 91% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 6% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 3% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 21% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Cohance Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Samsung BioLogics acquired XXX companies to date.
Last acquisition by Samsung BioLogics was XXXXXXXX, XXXXX XXXXX XXXXXX . Samsung BioLogics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Samsung BioLogics founded? | Samsung BioLogics was founded in 2011. |
| Where is Samsung BioLogics headquartered? | Samsung BioLogics is headquartered in South Korea. |
| Who is the CEO of Samsung BioLogics? | Samsung BioLogics's CEO is Mr. John Lim. |
| Is Samsung BioLogics publicy listed? | Yes, Samsung BioLogics is a public company listed on KRX. |
| What is the stock symbol of Samsung BioLogics? | Samsung BioLogics trades under 207940 ticker. |
| When did Samsung BioLogics go public? | Samsung BioLogics went public in 2016. |
| Who are competitors of Samsung BioLogics? | Similar companies to Samsung BioLogics include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics. |
| What is the current market cap of Samsung BioLogics? | Samsung BioLogics's current market cap is $53.4B |
| What is the current revenue of Samsung BioLogics? | Samsung BioLogics's last 12 months revenue is $3.6B. |
| What is the current revenue growth of Samsung BioLogics? | Samsung BioLogics revenue growth (NTM/LTM) is 20%. |
| What is the current EV/Revenue multiple of Samsung BioLogics? | Current revenue multiple of Samsung BioLogics is 14.7x. |
| Is Samsung BioLogics profitable? | Yes, Samsung BioLogics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Samsung BioLogics? | Samsung BioLogics's last 12 months EBITDA is $1.5B. |
| What is Samsung BioLogics's EBITDA margin? | Samsung BioLogics's last 12 months EBITDA margin is 41%. |
| What is the current EV/EBITDA multiple of Samsung BioLogics? | Current EBITDA multiple of Samsung BioLogics is 35.8x. |
| What is the current FCF of Samsung BioLogics? | Samsung BioLogics's last 12 months FCF is $540M. |
| What is Samsung BioLogics's FCF margin? | Samsung BioLogics's last 12 months FCF margin is 15%. |
| What is the current EV/FCF multiple of Samsung BioLogics? | Current FCF multiple of Samsung BioLogics is 99.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
